Due to extensive use, human exposure to multiple pyrethroid insecticides occurs frequently. Studies of pyrethroid neurotoxicity suggest a common mode of toxicity and that pyrethroids should be considered cumulatively to model risk. The objective of this work was to use a pyrethroid mixture that reflects human exposure to common pyrethroids to develop comparative toxicokinetic profiles in rats, and then model the relationship between brain concentration and motor activity. Data from a national survey of child care centers were used to make a mixture reflecting proportions of the most prevalent pyrethroids: permethrin, cypermethrin, β-cyfluthrin, deltamethrin, and esfenvalerate. The mixture was administered orally at one of two concentrations (11.2 and 27.4 mg / kg) to adult male rats. At intervals from 1 to 24 h, motor activity was assessed and the animals were sacrificed. Pyrethroid concentrations were measured in the blood, liver, fat, and brain. After controlling for dose, there were no differences in any tissue concentrations, except blood at the initial time point. Elimination half-lives for all pyrethroids in all tissues were < 7 h. Brain concentrations of all pyrethroids (when cis-and trans-permethrin were pooled) at the initial time point were proportional to their relative doses. Decreases in motor activity indicated dose additivity, and the relationship between pyrethroid brain concentration and motor activity was described by a four-parameter sigmoidal E max model. This study links environmental data with toxicokinetic and neurobehavioral assays to support cumulative risk assessments of pyrethroid pesticides. The results support the additive model of pyrethroid effect on motor activity and suggest that variation in the neurotoxicity of individual pyrethroids is related to toxicodynamic rather than toxicokinetic differences.
Pyrethroid pesticides are some of the most commonly applied residential-use insecticides in the United States, and survey data have repeatedly demonstrated the occurrence and co-occurrence of pyrethroids in residences and child care facilities (Morgan et al., 2004; Stout et al., 2009; Tulve et al., 2006) . Their presence in these locations is of concern because children spend the majority of their time indoors (Graham and McCurdy, 2004) and may be more susceptible than adults to pyrethroid-induced health effects , and nondietary ingestion of pyrethroids from indoor sources is an important exposure pathway for children (Morgan et al., 2007) .
Pyrethroids have 1-3 chiral carbons and are typically divided into two groups, depending upon the presence or absence of a cyano group at the α-carbon of the alcohol moiety. Both groups are neurotoxicants in mammalian test species but have different high-dose acute primary effects. In general, pyrethroids lacking the α-cyano group cause tremors (Type I or T), whereas α-cyano pyrethroids produce a salivation/choreoathetosis syndrome (Type II or CS). Both types primarily disrupt nervous system function by prolonging the opening of voltage-sensitive sodium channels (Narahashi et al., 1998; Soderlund et al., 2002) , although kinetic differences between the two types have been noted (Soderlund and Bloomquist, 1989) .
Studies of motor activity (Wolansky et al., 2006 (Wolansky et al., , 2009 , functional observational battery , and ion channel disruption ) have established that induced symptoms of neurotoxicity vary among the individual pyrethroids. In the motor activity studies, Wolansky et al. (2006) ranked the relative potency (RP) of several pyrethroids and demonstrated their dose additivity (Wolansky et al., 2009) . Citing the importance of the shared effect on sodium channels and the additive effect on motor activity, the U.S. EPA currently proposes that Type I and II pyrethroids share a common mechanism of toxicity and therefore present a cumulative risk (U.S. EPA, 2011) under the Food Quality Protection Act of 1996.
Because pyrethroids co-occur and can act additively, it is useful to establish toxicokinetic and neurotoxicity data reflecting the collective nature of the exposure. To date, most pyrethroid toxicokinetic reports are from single-analyte studies (Anadón et al., 1991 (Anadón et al., , 1996 (Anadón et al., , 2006 Godin et al., 2010; Hutson and Logan, 1986; Kim et al., 2008; Ohkawa et al., 1979) , and comparison of the results is problematic because of differences in doses, vehicles, and routes of administration (Crofton et al., 1995) . Further, these studies did not include a neurotoxicity assessment. Single-analyte toxicokinetic assessments by White et al. (1976) and Scollon et al. (2011) included neurotoxicity endpoints, but differences in study design and objectives severely limit comparison of the results. Multipyrethroid toxicokinetic profiles such as that by Marei et al. (1982) did not assess neurotoxicity or incorporate exposure-related concepts such as route and relative concentration in the study design. A literature review revealed no multipyrethroid toxicokinetic studies that included an effects endpoint.
The objectives of this research were to (1) use a mixture of pyrethroids that are most frequently detected in an indoor environment to develop comparative toxicokinetic profiles of individual pyrethroids in selected rat tissues, (2) evaluate whether pyrethroid toxicokinetics explain differences in RP reported by Wolansky et al. (2006 Wolansky et al. ( , 2009 , and (3) model the relationship between pyrethroid brain concentration and acute motor activity. A pyrethroid mixture was constructed using data from a national probabilistic sampling of care centers (Tulve et al., 2006) to determine the identity and relative proportions of the pyrethroids in the mixture. The pyrethroids selected were permethrin, cyfluthrin, cypermethrin, deltamethrin, and esfenvalerate. Rats were divided into two dose groups and dosed orally at one of two levels, with the total pyrethroid concentration in the groups equal to 1.5× (low dose) or 3.7× (high dose) the ED30 (effective dose 30-dose resulting in a 30% motor activity decrease) assuming dose-addition (Wolansky et al., 2009) . This research connects the multiple pyrethroids found in child care facilities with dose, toxicokinetics, target organ concentrations, and acute effects. This is a novel approach to the study of chemical mixtures that links exposure science with toxicology.
MATERIALS AND METHODS
Identification and formulation of pyrethroids for dosing mixture. The methods used to select the pyrethroids for this study have been described (Tornero-Velez et al., 2012) . Selection was based on a national study (Tulve et al., 2006) of a randomly selected set of 168 child care centers from across the United States. Data for a set of 15 pyrethroids and pyrethrins from indoor surface wipe floor samples were used. For each center, the fractional surface loading (FSL) of each pyrethroid was determined. For each pyrethroid species, its specific FSL was averaged across the centers. Many samples had nondetectable pyrethroid levels, so the analysis was limited to centers with higher pyrethroid surface loadings. To do this, the centers were sorted by total pyrethroid surface load (ng/cm 2 ) and the top 10% of centers (17 centers) identified. In the 17 centers, six pyrethroids accounted for 96.4% of the total pyrethroid surface loaded mass. Normalized by these six pyrethroids, the average FSLs were cypermethrin (0.288), deltamethrin (0.034), esfenvalerate (0.027), cis-permethrin (0.198), trans-permethrin (0.324), and β-cyfluthrin (0.129).
Using these values to apportion the pyrethroids, two dose mixture groups were constructed so that the total pyrethroid dose administered to each group was equal to 1.5× (low dose) or 3.7× (high dose) the ED 30 . These levels were chosen because both doses were expected to result in measurable concentrations of the pyrethroids in all tissues for at least 8 h, and also be disparate enough to result in tissue concentrations that were significantly different (between dose levels) to establish whether the toxicokinetics were dose dependent or independent. In addition, both dose groups were expected to have measurable loss of motor activity but not exhibit the high-dose acute primary effects of pyrethroid toxicity. The concentrations of the pyrethroids used in this study and their proportions in the dose mixtures are listed in Table 1 . The RP (Wolansky et al., 2006) and the group identity of each pyrethroid (Type I or II) are also listed in Table 1 . The relative toxicity of each pyrethroid in the mixtures was calculated by multiplying the percent of total dose for each pyrethroid in the dosing mixtures by its RP. The resulting order expressed as toxicity equivalents was permethrin < deltamethrin ≈ esfenvalerate < cypermethrin < β-cyfluthrin.
Chemicals and standards.
All chemicals used in this study were screened for pyrethroid contamination. Acetone, hexanes, ethyl acetate, methanol (Fisher Scientific, Pittsburgh, PA), and cyclopentane and acetonitrile (Honeywell Burdick & Jackson, Muskegon, MI) were of pesticide grade or better. All water used for sample analysis had resistance of 18 MΩ. Primary calibration standards including cis-permethrin (99%), trans-permethrin (94%), deltamethrin (99%), cypermethrin (98%), cyfluthrin (98%), and esfenvalerate (98%) were purchased from Absolute Standards (Hamden, CT). Ring-labeled (phenoxy-13 C 6 ) pyrethroids used as internal standards or surrogates were purchased from Cambridge Isotope Laboratories (Andover, MA) and included cis-permethrin, trans-permethrin, cyfluthrin, and cypermethrin. The physical and chemical properties of the pyrethroids used in the dosing solutions have been described previously (Wolansky et al., 2006) . Each was provided by its respective manufacturers as follows: permethrin and cypermethrin (FMC Corporation, Philadelphia, PA), deltamethrin and β-cyfluthrin (Bayer Based on presence or absence of a cyano group at the α-carbon of the alcohol moiety and the high dose acute physiological effects.
b Potency based on ED 30 for effect on motor activity relative to deltamethrin as the index pyrethroid (Wolansky et al., 2006 Calibration standards were prepared in reconstituted cleaned extracts of blank tissues and were 1, 10, 25, 50, 75 and 100 ng/ml. Two additional sets of calibration standards were prepared for samples for which the calculated concentration of one or more of the pyrethroids extended beyond the original calibration curve. These standards were also prepared in extracted and cleaned tissues from untreated animals and ranged from 0.25 ng/ml to 2.50 ng/ml, and from 25 to 1500 ng/ml. Animals. Male 60-day-old Long Evans rats were purchased from Charles River Laboratories (Raleigh, NC) and allowed to acclimate for a minimum of 4 days in a facility approved by American Association for the Accreditation of Laboratory Animal Care. Rats were housed in pairs in cages (45 × 24 × 20 cm) lined with heat-treated pine shavings bedding. Temperature, humidity, and light:dark photoperiod were maintained at 21°C ± 2°C, 50 ± 10%, and 12L:12D, respectively. Feed (Purina Rodent Chow 5001, Barnes Supply Co., Durham, NC) and tap water were provided ad libitum.
Experimental. The treatment groups in this study consisted of a corn oil control group and two dose mixture levels. Stock mixtures of the pyrethroids at appropriate concentrations were dissolved in corn oil immediately before administration. The preparation was stirred with intermittent heating (maximum 40°C−45°C) for at least 15 min. All doses (Table 1) were delivered orally in corn oil at 1 ml/kg. Control animals received corn oil (1 ml/kg) only. At 1, 2, 4, 8, or 24 h postdosing, the motor activity of each animal was assessed over a 1-h period, then the animals were sacrificed (2.5, 3.5, 5.5, 9.5, or 25.5 h postdosing), and tissue samples were taken. At 1, 2, 4, and 8 h, there were four control, six low-dose, and four high-dose animals in each group. At 24 h, there were two controls, four low-dose, and four high-dose animals. All animal procedures were approved by the U.S. EPA's National Health and Environmental Effects Research Laboratory's Institutional Animal Care and Use Committee.
Motor activity. The test used for motor activity was conducted as described by Wolansky et al. (2006) . Briefly, animals were placed in a series of 16 figure-8 mazes, each with 12 phototransistor/photodiode pairs. Each beam interruption was recorded as an activity count and captured both horizontal and vertical movements. Testing lasted for 1 h, and total motor activity was the sum of horizontal and vertical counts. Total activity of each test animal was calculated as a percentage of the mean activity of the control animals at the relevant time point.
Tissue collection and processing. Anesthesia was induced by CO 2 , and cardiac blood was taken via heart puncture during exsanguination. Whole blood was collected in 2-ml aliquots and frozen in a methanol/dry ice bath. Whole brain (seperated at the level of the foramen magnum), abdominal subcutaneous fat, and liver tissues were collected from each animal, postmortem. These samples were flash frozen in liquid nitrogen and homogenized. All tissue samples were stored at −80°C.
The procedures used to extract and purify the pyrethroids were similar to that developed for analysis of deltamethrin in rat tissues (Godin et al., 2010) . The mass of brain used for each sample was 350-400 mg and was weighed while frozen. Frozen brain, liver, and fat were pulverized in a Spex CertiPrep 6850 freezer/mill (Metuchen, NJ) to form a fine homogenous tissue powder. Blood samples were prepared using the 2-ml aliquots. Prior to extraction, both brain and blood were placed in a glass culture tube and spiked with 13 C 6 -trans-permethrin that served as a surrogate standard. Samples were vortex extracted for 10 min with 5 ml acetone:hexane (2:8, vol/vol) and then centrifuged at 3000 rpm for 10 min. The organic layer was transferred to another culture tube. The extraction was repeated two additional times with 3 ml acetone:hexane (2:8, vol/vol). The combined organic extract was dried under nitrogen and redissolved in 1 ml hexane. The extracts were loaded onto 500 mg silica Solid Phase Extraction columns (Waters, Inc., Milford, MA), rinsed with 5 ml hexane, and eluted with 5 ml of 6% ethyl acetate in hexane. Eluants were dried under nitrogen and then dissolved in 1 ml methanol:water (9:1, vol/vol). Internal standards were added and the samples transferred to autosampler vials. All samples were stored at −20°C until analysis.
Fat and liver concentrations were determined using 250-300 mg samples that were weighed while still frozen. Prior to extraction, both tissue types were placed in culture tubes and spiked with 13 C 6 -trans-permethrin that served as a surrogate standard. Samples were extracted once as described above, and the organic layers were collected. The process was repeated two additional times for the liver with 3 ml acetone:hexane (2:8, vol/vol) and once for the fat with 3 ml acetone:hexane (2:8, vol/vol). The extracts were filtered through polytetrafluoroethylene filters (0.45 μm), which were then washed with 3.5 ml acetone:hexane (2:8, vol/vol). The organic phase was dried under nitrogen and dissolved in 3 ml cyclopentane:ethyl acetate (3:7, vol/vol). Pyrethroids were separated from lipids via gel permeation chromatography using an OI Analytical Biobead Prep Column J2 Scientific (College Station, TX) and a (3:7, vol/vol) cyclopentane:ethyl acetate isocratic mobile phase (5 ml/min). Purified extracts were dried under nitrogen and dissolved in 2 ml hexane. Remaining lipids were removed by thrice partitioning the extracts with an equal volume of acetonitrile saturated with hexane. The acetonitrile fractions were combined, dried under nitrogen, and dissolved in 1 ml methanol:water (9:1, vol/vol). Internal standards were added and the samples transferred to autosampler vials. All samples were stored at −20°C until analysis.
Instrument analysis. Sample analysis was performed using an AB SCIEX model API 4000 Liquid Chromatography-Tandem Mass Spectrometry (LC/ MS/MS) system configured with a Turbo Ion Spray. Supplementary tables 1 and 2 list the LC conditions and MS/MS settings. Under the conditions used, the cis-trans isomers of permethrin were separated, but those isomers were not resolved for cypermethrin or cyfluthrin.
Method validation and limits of detection and quantitation.
The mean method recoveries of the pyrethroids from each type of tissue were determined using four replicates each of 10 and 75 ng tissue spikes. The limit of detection (LOD) and limit of quantitation (LOQ) for each pesticide were calculated using 16 replicates of each tissue type spiked with mixture that contained 250, 500, 750, or 1250 pg of each pyrethroid. The samples were processed and analyzed four separate times over a 1-week period. Analyte concentrations were pooled to calculate group standard deviations of the estimated concentrations. Using the standard deviations as the dependent variable and the theoretical concentrations as the independent variable, least squares regression was used to calculate the intercept. The intercept of the equation was defined as S 0 with the LOD approximated by 3 × S 0 , and the LOQ approximated by 10 × S 0 (Taylor, 1987) .
Quality control and quality assurance. A set of matrix-based calibration standards was analyzed immediately before and after each sample set. Quality control procedures included remaking standards when the initial calibration curve data did not fit a first-order equation with r 2 ≥ 0.99. When the slope of the postrun calibration curve differed substantially from the initial, the LC and/ or mass spectrometer was cleaned and the samples were reanalyzed. A tissue blank and a midlevel tissue spike sample were each analyzed after each six samples in every set.
The acceptable range for surrogate recovery in the samples was set at 80−120%. No surrogate corrections were made to calculated concentrations. When sample surrogate recoveries were outside the acceptance criteria, additional tissue was processed and analyzed. If no tissue was available, then the result for that sample was not included in any further analyses. Data below the LOQ were not used.
Data analysis. All data were processed and analyzed using SAS/STAT software, version 9.2 (SAS Institute, Cary, NC). Prior to analysis, the data were stratified by pyrethroid, tissue, time, and dose (and replicate averaged within rat) and tested to determine data distribution type. The assumption of normality was supported by Shapiro-Wilk statistics for a majority (> 85%) of the distributions; therefore, statistical tests for normally distributed data were used.
ANOVA was used to evaluate method precision and the effect of rats, replicates, and their interaction on the variability in measured residues within each PYRETHROID KINETICS AND EFFECT ON MOTOR ACTIVITY of the tissue, time, and dose groupings. In addition, paired Student's t-tests were used to compare replicate measurements, also within tissue, time, and dose groupings.
Based on the report by Wolansky et al. (2006) , peak tissue concentration (brain, blood, and liver) was presumed to occur at or before the 2.5-h time point. The assumption was verified by t-test comparisons of concentrations at 2.5 and 3.5 h, and the 2.5-h time point was used to compare tissue uptake by pyrethroid and dose group, and as the first time point in calculation of the elimination constants. Predicted tissue-blood partition coefficients for all pyrethroids were calculated using the octanol-water partition coefficient-based algorithm developed by Poulin and Krishnan (1995) .
Elimination constants were estimated using data from 2.5 through 9.5 h inclusive. Data from the 25.5-h time point were excluded due to a high percentage of samples with concentrations below the LOQ. First-order elimination was assumed, and times of sample collection were regressed against transformed residue concentrations (natural logarithmic) grouped by dose and tissue. A generalized linear model (PROC GLM) was used to test each pyrethroid in each tissue for heterogeneity between dose groups and to determine whether each elimination slope was statistically different from zero. Where the slope was not different from zero, that dose group was not used in calculating the pyrethroid half-life. Where the regression slopes of the dose groups were homogeneous and both different from zero, half-lives (t 1/2 ) and corresponding confidence bounds of individual pyrethroids in each tissue were estimated using dose-adjusted and dose-pooled data. Then, the heterogeneity of half-lives between individual pyrethroids was evaluated by tissue, also using PROC GLM.
Relative proportions were calculated for individual pyrethroid concentrations at 2.5 h. To do this, individual pyrethroids were normalized to equal a percentage of the total pyrethroid load for that tissue and animal. The expected contribution of each pyrethroid equaled the percent pyrethroid of the total pyrethroid dose as listed in Table 1 . Tissue-to-blood concentrations were calculated by dividing each tissue concentration (within an animal) by the corresponding blood concentration.
Means and standard deviations of motor activity of both doses were calculated at each time point, and a four-parameter logistic, or sigmoidal E max model (Dmitrienko et al., 2007) , was used to relate variability in motor activity to total pyrethroid brain concentration:
where Y is the control-normalized response, E max and E min are the upper and lower bounds of the response, X is the total pesticide concentration, EC 50 is the concentration at which the median response is attained (or inflection point of the curve), and h is the hill coefficient (slope). Pyrethroids were modeled individually, then by Type (I and II), and finally as a group. Only data from rats with brain concentrations above the LOQ were included, and data from the final time point were not used. Statistical significance was assigned at p ≤ 0.05.
The hypothetical relative percent contributions of individual pyrethroids in brain tissue in reducing motor activity were estimated as follows:
where RPC ij is the relative percent contribution of pyrethroid i to measured response at hour j, x ij is the brain tissue concentration of pyrethroid i at hour j, and RP i represents the RP of pyrethroid i (Table 1) , assumed to be constant across time. PROC REG was used to calculate the rate of change (in percent contribution) over time for each pesticide. Statistical significance was assigned at p ≤ 0.05.
RESULTS

Method Validation: LOD/LOQ
The pooled percent recoveries (± SE) of all pyrethroids from each tissue type were as follows: blood, 82 ± 7; brain, 92 ± 7; fat, 84 ± 7; and liver, 85 ± 6. The calculated LOQ for all pyrethroids in brain, liver, and fat were less than 3 ng/g and less than 300 pg/ml in blood.
All samples from pyrethroid-dosed animals had quantifiable concentrations of all pyrethroids, at both 2.5-and 3.5-h time points. Measurable concentrations of all pyrethroids were present in all fat samples at all time points. At 5.5 h, more than 50% of the liver samples (low-dose group) had concentrations of trans-permethrin (67%) and β-cyfluthrin (83%) that were below the LOQ. At 9.5 h, all liver concentrations of trans-permethrin and β-cyfluthrin, and 66% of deltamethrin concentrations, were below the LOQ. Esfenvalerate in blood (low-dose group; 83% ≤ LOQ) at 9.5 h was the only other time point/analyte where more than 50% of the concentrations were below the LOQ. As stated earlier, data from the 25.5-h collection were not used due to a lack of quantifiable data from tissues other than fat. 
Tissue Uptake
At the initial time point (2.5 h), higher doses generally resulted in higher mean tissue concentrations for each pyrethroid ( Table 2 ). The dose group differences were statistically significant for all pyrethroids in all tissues except for esfenvalerate in brain and cypermethrin, deltamethrin, trans-permethrin, and β-cyfluthrin in fat. Comparison of doseadjusted tissue concentrations (tissue concentration/dose) at 2.5 and 3.5 h indicated that maximum uptake occurred at or before the 2.5-h time point.
After adjusting for dose, concentrations were not statistically different between the two dose levels at 2.5 h for any tissue except blood, where the mean concentrations of all pyrethroids in the high-dose group remained higher than in the low-dose group. These differences were significant for cypermethrin (p = 0.014), deltamethrin (p = 0.019), trans-permethrin (p = 0.002), and β-cyfluthrin (p = 0.025), but not for esfenvalerate (p = 0.083) and cis-permethrin (p = 0.080). At the 3.5-h time point, t-tests of dose-adjusted concentrations showed that these differences in blood had disappeared.
At 2.5 h, trans-permethrin, comprising ≤ 13% of the total pyrethroid load in each tissue, had the largest difference in relative tissue concentration compared to relative dose concentration (31% of total pyrethroid dose). Using Tables 1 and  2 , no consistent relationships appeared between relative tissue concentrations and relative dose concentration, except in the brain. All pyrethroids in brain, except cis-permethrin (48%) and trans-permethrin (5%), were consistent with their relative dosing proportions. However, when cis and trans isomers are summed, the relative proportion of permethrin is also close to its percentage of 52% in the dosing solution.
The theoretical partition coefficients (Poulin and Krishnan, 1995) predicted high tissue-to-blood ratios and little variation for all pyrethroids with coefficients ranging from 21 to 22 (liver to blood), 434 to 438 (fat to blood), and 28.1 to 28.4 (brain to blood). As seen in Table 3 , the tissue-to-blood ratios for all tissues at the initial time point of this study indicate that the partitioning was much lower and more varied than predicted. Mean brain-to-blood ratios of the high-dose group were all less than those of the low-dose group, and the ratios for cypermethrin, deltamethrin, and esfenvalerate were all less than 1. Similar dose-dependent differences were observed for all pyrethroids for the fat-to-blood ratios and, as in the brain, the fat-to-blood ratios of cypermethrin, deltamethrin, and esfenvalerate were all lower than those of the permethrins and β-cyfluthrin. The doserelated dependency was repeated in liver-to-blood ratios (initial time point), with the exception of cypermethrin. As with the other tissues, the liver-to-blood ratio of β-cyfluthrin was nearer to the ratio of permethrins than the ratio of cypermethrin and deltamethrin, the two most similar type II pyrethroids. Except low-dose deltamethrin, the liver-to-blood ratios were all ≥ 1.
Tissue Elimination
The calculated elimination constants and relevant statistics for each pyrethroid (by dose group and tissue) are provided in the supplementary material. The half-lives, estimated using Mean brain-to-blood concentration ratio (± SEM) Low 2.5 0.5 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 2.6 ± 0.4 3.2 ± 1.1 2.1 ± 0.4 High 2.5 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 1.2 ± 0.6 0.7 ± 1 0.7 ± 0.4 All 3.5 0.5 ± 0.1 0.5 ± 0.1 0.8 ± 0.4 3.3 ± 1.3 3 ± 1.4 2.4 ± 0.9 5.5 1.7 ± 0.2 3.4 ± 1.0 4.6 ± 0.9 16.3 ± 5 19.5 ± 12.3 7.4 ± 1.5 9.5 2.2 ± 0.6 4.3 ± 1.6 3.4 ± 1.2 49.2 ± 15.2 15.8 ± 2.7 7.4 ± 1.9 25.5 3.4 ± 1.5 NA a NA 26.5 ± 12.3 NA NA Mean fat-to-blood concentration ratio (± SEM) Low 2.5 4 ± 1 4 ± 0 6 ± 1 11 ± 2 58 ± 20 17 ± 4 High 2.5 2 ± 0 1 ± 0 3 ± 0 5 ± 1 9 ± 2 6 ± 1 All 3.5 6 ± 2 8 ± 4 16 ± 9 9 ± 1 38 ± 11 36 ± 18 5.5 33 ± 7 44 ± 10 69 ± 13 136 ± 58 372 ± 120 187 ± 36 9.5 134 ± 41 142 ± 30 119 ± 42 1056 ± 424 1476 ± 507 901 ± 232 25.5
1963 ± 868 462 ± 63 NA 3153 ± 975 1895 ± 729 6512 ± 2683 Mean liver-to-blood concentration ratio (± SEM) Low 2.5 1.0 ± 0.2 1.0 ± 0.1 2.0 ± 0.2 1.8 ± 0.2 2.8 ± 0.7 2.1 ± 0.3 High 2.5 1.6 ± 0.1 0.6 ± 0 1.3 ± 0.2 1.1 ± 0.1 1.4 ± 0.3 1.7 ± 0.2 All 3.5 1.4 ± 0.1 0.7 ± 0 2.3 ± 0.7 1.3 ± 0.1 1.9 ± 0.4 7.6 ± 5.6 5.5
1.2 ± 0.1 1 ± 0.1 3.4 ± 1.5 2.6 ± 0.7 9.4 ± 5 2.2 ± 0.8 9.5 2.2 ± 0.1 4.3 ± 0.3 3.4 ± 0.7 49.2 ± 0.7 15.8 ± 2 7.4 ± 0.8 25.5 0.4 ± 0.1 NA NA NA NA NA a Insufficient data were available to calculate a ratio.
PYRETHROID KINETICS AND EFFECT ON MOTOR ACTIVITY
313 pooled high and low group data (where applicable) for blood, brain, and liver, are listed in Table 4 . Half-lives in fat were not calculated because only one of the rate constants (deltamethrin; low dose, p= 0.04) was statistically different from zero. The half-lives were less than 2 h in blood, 3-6.2 h in brain, and 2.3 h or less in liver. The within-tissue half-lives of the pyrethroids were not statistically different in blood or liver. In brain, the half-life of β-cyfluthrin was statistically less than those of all other pyrethroids except trans-permethrin. The half-life of cypermethrin was statistically different from the two pyrethroids with the longest half-lives: cis-permethrin and esfenvalerate, as well as β-cyfluthrin. Finally, the half-life of trans-permethrin was statistically different from that of esfenvalerate.
Motor Activity and Brain Concentration of Pyrethroids
Both mixture doses evoked mild clinical signs of pyrethroid toxicity. Restlessness and episodes of nonlocomotor behaviors such as scratching, pawing, burrowing, and body shakes were observed along the initial 2-3 h after dosing, but there were no signs of high-dose pyrethroid symptoms such as hypersalivation, whole-body tremors, and choreoathetosis in any animals. The lack of a full expression of type-specific signs of pyrethroid toxicity was consistent with the mild pyrethroid-specific signs of neurotoxicity observed in one of the pyrethroid mixture study where total doses used were higher (Wolansky et al., 2009) .
The results of motor activity (as a percentage of control), for each time period, are presented in Figure 1 . The time period of peak effect (largest mean decrease) for the low-dose group was 1-2 h postdosing. The peak effect for the high-dose group occurred during the 2-to 3-h interval. After the peak effect, motor activity of both groups increased over the next two time periods, after which no additional increase was apparent.
Except esfenvalerate, brain concentrations of individual pyrethroids fit the sigmoidal E max model to predict decreases in motor activity. Similarly, models of Type I and II groups were both statistically significant. Therefore, the final model (Fig. 2) with estimated high and low motor activity thresholds of 113% (p < 0.0001) and 34% (p = 0.16), respectively, of controls. The slope of −2 (between the threshold values) indicated that a 2 ng/g increase in total pyrethroid brain concentration resulted in a 1% decrease in motor activity, and the estimated EC 50 was 217 ng/g (p = 0.0006).
Excluding trans-permethrin, all regression slopes of estimated relative percent contribution (to total pyrethroid concentration) were statistically significant (p < 0.05). The slopes for cypermethrin and cyfluthrin were negative, whereas the slopes for esfenvalerate, deltamethrin, and cis-permethrin were positive. At 2.5 h the estimated relative percent contributions were as follows: β-cyfluthrin, 42%; cypermethrin, 21%; deltamethrin, 13%; esfenvalerate, 13%; cis-permethrin, 8%; and trans-permethrin, 1%. At 9.5 h, these values had changed as follows: β-cyfluthrin, 23%; cypermethrin, 17%; deltamethrin, 17%; esfenvalerate, 26%; cis-permethrin, 18%; trans-permethrin, 1%.
DISCUSSION
Implications of Study Design
The use of low-dose, empirically based pyrethroid mixtures to estimate toxicokinetic parameters is a significant advance in connecting exposure science with toxicology. Although simplified in its use of a single-exposure pathway and single-dose design, this study incorporated the concept of environmentally relevant cumulative dose in evaluating tissue uptake and elimination. Use of a mixture provided direct comparative data for uptake and elimination of each pyrethroid in each tissue. Simultaneous dosing with five pyrethroids that included representatives of Types I and II helped address whether nontarget site kinetic differences were important correlates of motor activity. Although not assessed directly, potential interactions between the pyrethroids were inherent in this study design and reflect interactions expected from actual exposures.
Kinetics
Liver. Relative to dose, liver concentrations of trans-permethrin at 2.5 h were much lower than concentrations of cis-permethrin and other pyrethroids (Tables 1 and 2 ). This result was unexpected due to the similarity of half-lives of all pyrethroids in both blood and liver (Table 4) , and the narrow range (21-22) of predicted pyrethroid liver-to-blood partition coefficients. It is possible that the trans-permethrin concentrations resulted from increased binding of trans-permethrin by hepatic or circulatory proteins, but literature reports suggest that covalent binding rates of pyrethroids by hepatic proteins are generally low. An in vivo study (Hoellinger et al., 1983) found that less than 6% of each of the type I pyrethroids cismethrin and bioresmethrin were covalently bound to rat liver proteins.
In addition, Catinot et al. (1989) found the covalent binding in homogenates of rat liver to be less than 10% for the type II pyrethroids deltamethrin and cypermethrin. Unfortunately, a literature review revealed no reports of cis-or trans-permethrin hepatic protein binding.
The lower trans-permethrin concentrations may have resulted from significant levels of intestinal metabolism, or less absorption. Crow et al. (2007) and Nakamura et al. (2007) also reported that intestinal and hepatic cytosol carboxylesterases could cleave the ester linkage of trans-permethrin but not that of deltamethrin or cis-permethrin. However, Nakamura et al. (2007) reported rat intestinal hydrolysis rates to be only 33% of the liver, and Crow et al. (2007) estimated that intestinal hydrolysis accounted for only 2.5% of the total hydrolytic activity for trans-permethrin in rats. The dose-adjusted concentration (dose groups pooled) of β-cyfluthrin in the liver at 2.5 h was lower than that of cis-permethrin and cypermethrin. This was unexpected because β-cyfluthrin is a type II pyrethroid, which differs from cypermethrin by addition of fluorine at the fourth position of the alcohol moiety and enrichment of two pairs of diasteromers, specifically, (S)α, 1(R)-cis-+ (R)α, 1(S)-cis-; (S)α, 1(R)-trans-+ (R)α, 1(S)-trans-. Unfortunately, there appears to be no published reports describing cyfluthrin toxicokinetics.
Single pyrethroid in vitro studies have shown pyrethroid-specific differences in rates of metabolism and the importance of different pathways. In general, the predicted order of clearance rates for pyrethroids (Soderlund and Casida, 1977) in mixed esterase/oxidase systems is as follows: trans esters (unsubstituted at primary alcohol) > cis esters (unsubstituted at primary alcohol) > trans esters (substituted at α carbonyl) > cis esters (substituted at α carbonyl), and it is not clear why the liver half-lives of all pyrethroids in the current study were approximately equal. As Soderlund et al. used mouse microsomal preparations, it is possible that the disparity is due to in vivo versus in vitro or species-related differences. Literature reports of in vivo or in vitro metabolic rates determined using a pyrethroid mixture are largely absent. However, there is some evidence of interaction between the cis/trans isomers of permethrin. Scollon et al. (2009) demonstrated an in vitro cis/trans interaction between permethrin isomers whereby the clearance of the trans-isomer was slowed slightly in the presence of the cis isomer and elimination of the cis isomer was slowed slightly.
Clearly, more in vitro work evaluating interactions of pyrethroids and their cis/trans isomerism in esterase/ oxidative-mediated metabolic systems would be useful. These data suggest that intestinal metabolism may explain some of the differences between cis-and trans-permethrin toxicokinetics, but other mechanisms, such as differences in absorption, may also play a role. Further research needs to be performed to determine whether the loss of the trans-isomer extends to cypermethrin and β-cyfluthrin as both are also cis/trans mixtures.
PYRETHROID KINETICS AND EFFECT ON MOTOR ACTIVITY
Blood. The transient dose-dependent concentration of the pyrethroids in the blood at 2.5 h indicates nonlinear absorption kinetics. The nonlinearity may be attributed to absorption rather than metabolism because of the consistency between the estimated elimination half-lives of the pyrethroids (Table 4) in blood. The pyrethroids in the high-dose group may have been absorbed more efficiently because they were more concentrated in the corn oil vehicle. For example, Wolansky et al. (2007) found that reducing the volume of the corn oil vehicle fivefold increased the potency of orally administered bifenthrin by a factor of 2. Further, in the current study, all pyrethroids showed this dose-related difference regardless of their relative concentration in the mixture, suggesting the effect was related to the total pyrethroid concentration rather than to the concentration of the individual pesticides. Although Godin et al. (2010) examined the bioavailability of deltamethrin and found it to be dose independent (0.3 and 3 mg/kg), the total pyrethroid doses in this study (Table 3) were higher than the doses of deltamethrin in the cited study.
When the two dose groups were pooled at 2.5 h, the liver-toblood ratio of deltamethrin (0.88 ± 0.24) was similar to the 1:1 ratio reported by Mirfazaelian et al. (2006) , but was higher than the 2:7 ratio reported by Godin et al. (2010) . Published reports with this type of in vivo data for the other pyrethroids are lacking. In the current study, the liver-to-blood ratios of all pyrethroids were 1:1 or greater and half-lives of all pyrethroids in blood were not different from half-lives in liver. In addition, the liver-to-blood ratio of deltamethrin was significantly lower (p ≤ 0.05) than that of all other pyrethroids except cypermethrin. As stated earlier, differences in octanol-water−based partition coefficients estimations are very small and do not explain differences in liver-to-blood ratios. Alternatively, differences in blood protein binding may provide an explanation, but studies of the capacity of serum proteins to bind permethrin (Abu-Qare and Abou-Donia 2002), cismethrin, and bioresmethrin (Hoellinger et al. 1985) suggest that this pathway is not significant.
Fat. Fat functioned effectively as a sink for the pyrethroids in this study as all were more concentrated in fat than in other tissues. The rapid uptake of the pyrethroids in fat, followed by no detectable elimination from that tissue, was expected, as pyrethroids are lipophilic and lipases are not thought to be important in their metabolism (Crow et al., 2007) . The results are consistent with slow elimination rates observerd in in vivo studies of deltamethrin (Godin et al., 2010; Mirfazaelian et al., 2006) . Assuming that fat comprises 7% of total rat body mass (Schoeffner et al., 1999) , the percent of each pyrethroid in fat was less than 2% of its administered dose. The uptake by adipose tissue is low compared with other lipophillic chemicals such as dioxin (Diliberto et al., 1996) . Because the octanol-water partition coefficients of pyrethroids and dioxin are comparable, the difference in adipose tissue distribution is likely due to a higher rate of pyrethroid metabolism in other tissues.
Except low-dose esfenvalerate, concentrations in fat did not increase during the study (Supplementary table 3) . Therefore, the data did not support significant redistribution of the pyrethroids from other tissues to the fat. In addition, the long half-life of the pyrethroids in the fat and rapid metabolism in liver and blood precluded adipose tissue from being a secondary source for measurable redistribution to other tissues.
Brain Kinetics and Motor Activity
High/low dose−related differences in blood concentrations at 2.5 h were not reflected in the brain. In addition, all brain-toblood ratios were much lower than predicted by their partition coefficients, suggesting a limitation in crossing the blood-brain barrier that affected all study pyrethroids. Brain-to-blood ratios did not segregate into Type I and Type II pyrethroids (Table 3) , nor did they appear to be a function of the absolute concentration in the blood or differences in brain elimination rates. Ultimately crossing the blood-brain barrier by each pyrethroid is likely determined by its tertiary structure, and a more sophisticated analysis of pyrethroid structure-activity relationships would be useful.
The observed differences in t 1/2 of the pyrethroids in the brain pyrethroid did not sort according to the rates predicted from oxidative and hydrolytic activity in liver or serum. Interestingly, Ghiasuddin and Soderlund (1984) found that the specificity of mouse brain esterases was different from that of the mouse liver esterases and the brain esterases demonstrated activity toward trans-permethrin and fenvalerate but were relatively inactive in the hydrolysis of cis-permethrin or deltamethrin. Potentially, this may also occur in the rat.
An important finding of this study was the similarity between the relative proportion of each pyrethroid in the brain and its percentage in the dosing mixture (after summing cis-and trans-permethrin isomers) at the 2.5-h time point. Therefore, administered dose predicted relative brain concentrations at a time point near the peak effects of individual pyrethroids on motor activity as noted by Wolansky et al. (2009) . This may simplify efforts to model low-dose cumulative risk from these pyrethroids because it appears that metabolic variations in other tissues were offset by differences in partitioning from blood to brain. The similarity of the relative proportions of the pyrethroids in the brain and dosing solution implies that differences in RP of each pyrethroid are not a function of toxicokinetic differences. Rather, their relative impact on motor activity is likely dependent on specific interactions with ion channels.
The decreases in motor activity of 34% (low dose, 1.5× ED 30 ) and 67% (high dose, 3.7× ED 30 ) at the times of peak effect (1-2 h low-dose group, 2-3 h high-dose group) agree with the decrease of approximately 40 and 60% predicted by Wolansky et al. (2009) and therefore support those researchers' pyrethroid dose additive effects model. The occurrence of greatest mean decrease in motor activity at 1-3 h is consistent with the time to peak effect for the individual pyrethroids of 1.5-2.0 h, 316 STARR ET AL. also reported by Wolansky et al. (2009) . The return to normal motor activity function several hours postdosing observed in that study also occurred in this study (Fig. 2) . In addition, the minimum dose threshold, linear dose-response range, and asymptotic nature of the maximum response in the Wolansky model were apparent in four-parameter model of motor activity and pyrethroid brain concentration in this study (Fig. 2) . The brain concentrations of the pyrethroids in this study provide the toxicokinetic data underlying the dose additive pyrethroid effects model and assist the interpretation of that model by showing the relationship between response and the concentration of this mixture of pyrethroids in the brain. Further, the fit of the four-parameter model (p < 0.001) and the overlap of the data from the two dose groups at four time points indicate that the pyrethroid brain concentration is the important determinate of motor activity and that dose and time predict brain concentration and therefore effect. This supports research by Scollon et al. (2011) , who found a similar relationship between bifenthrin dose, brain concentration, and motor activity.
Although the contribution of individual pyrethroids to loss of motor activity could not be directly measured, the hypothetical relative contributions suggest that β-cyfluthrin would be the greatest contributor to loss of motor activity at 2.5 h, and cis/trans-permethrin the least. At 9.5 h, individual pyrethroids would contribute similarly to total toxicity. It is important to note that these estimates should be interpreted cautiously as Wolansky et al. (2006) determined RPs in single-chemical studies using multiple doses at the time of peak effect. Additional data on RP from single-chemical, time-series studies would provide insight into the validity of combining RP and tissue concentration across time in this model.
CONCLUSIONS
Environmentally relevant dosing schemes may be used as a conceptual model in future studies of chemical mixtures. In this study, it added a practical component to a toxicokinetic study that would be useful in cumulative risk assessments.
Distribution of the pyrethroids to all tissues was rapid, with maximum concentrations likely at, or before, the 2.5-h time point. Excepting blood at 2.5 h, relative tissue concentrations were dose independent. In liver, blood, and fat, there was no apparent relationship between uptake and pyrethroid relative dose concentrations, lipid solubility, or structural groupings. The most notable results were the very low proportionate tissue concentrations of trans-permethrin.
Initial concentrations of cypermethrin, deltamethrin, β-cyfluthrin, and esfenvalerate in brain reflected their relative proportion in the dosing solution. When concentrations of cis and trans-permethrin were summed, the relative brain permethrin concentration also reflected dose.
The similarity of the elimination half-lives of individual pyrethroids in blood and liver was unexpected considering in vitro differences of previous studies. In brain, half-life differences between the slowest and most rapidly cleared pyrethroids were unrelated to relative dose concentration or obvious differences in chemical structure.
Brain concentration was predicted by dose and time, and pyrethroid brain concentration predicted motor activity. Relative uptake and elimination of the pyrethroids in brain did not correspond with the Type I and Type II groupings or the RPs noted in previous studies. Therefore, differences in pyrethroid kinetics are insufficient to explain behavioral responses observed in previous studies.
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